OVERVIEW

Chonluten 20 mg (Bioregulator) is a short synthetic peptide tripeptide — often referred to as T‑34 or EDG — studied in laboratory and preclinical research for its potential role in respiratory and epithelial cell regulation. Research suggests that Chonluten can influence gene expression patterns associated with inflammation, antioxidant defense, and cellular repair, especially within lung tissues and, to a lesser extent, the gastrointestinal tract. Preclinical models indicate it may modulate key signaling pathways involved in cytokine balance, oxidative stress response, and epithelial integrity, leading researchers to explore its relevance in pulmonary tissue regeneration, bronchial mucosal stability, and inflammatory regulation under controlled conditions. Its small size and sequence enable it to interact at the cellular level, making it a useful tool in mechanistic studies of peptide‑mediated transcriptional control and tissue‑specific bioregulation.

Despite scientific interest, Chonluten is not approved for therapeutic use by the U.S. Food and Drug Administration and remains strictly a research compound. Products labeled as Chonluten 20 mg are sold for laboratory use only under research designations, meaning safety, human dosing, and clinical efficacy have not been established, and quality can vary between suppliers. It is not intended for human or veterinary consumption and is typically studied in vitro or in animal models to investigate fundamental aspects of peptide regulation, gene expression, and tissue health